Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial

INTRODUCTION: We report the 48-week results of an ongoing study to assess the efficacy and safety of switching older people with HIV to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF). METHODS: This was a 96-week, phase 3b, open-label, single-arm study (GS-US-380-4449; NCT03405935). Virolo...

Descripción completa

Detalles Bibliográficos
Autores principales: Maggiolo, Franco, Rizzardini, Giuliano, Molina, Jean-Michel, Pulido, Federico, De Wit, Stephane, Vandekerckhove, Linos, Berenguer, Juan, D’Antoni, Michelle L., Blair, Christiana, Chuck, Susan K., Piontkowsky, David, Martin, Hal, Haubrich, Richard, McNicholl, Ian R., Gallant, Joel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116430/
https://www.ncbi.nlm.nih.gov/pubmed/33686573
http://dx.doi.org/10.1007/s40121-021-00419-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116430/
https://www.ncbi.nlm.nih.gov/pubmed/33686573
http://dx.doi.org/10.1007/s40121-021-00419-5

Ejemplares similares